These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 11851355

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.
    Ryan TD, Rothstein EC, Aban I, Tallaj JA, Husain A, Lucchesi PA, Dell'Italia LJ.
    J Am Coll Cardiol; 2007 Feb 20; 49(7):811-21. PubMed ID: 17306712
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension.
    Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T.
    J Mol Cell Cardiol; 2006 Dec 20; 41(6):989-97. PubMed ID: 16979182
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy.
    Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Böhm M, Pauschinger M, Schultheiss HP, Tschöpe C.
    Basic Res Cardiol; 2008 Jul 20; 103(4):319-27. PubMed ID: 18347835
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
    Klotz S, Danser AH, Foronjy RF, Oz MC, Wang J, Mancini D, D'Armiento J, Burkhoff D.
    J Am Coll Cardiol; 2007 Mar 20; 49(11):1166-74. PubMed ID: 17367660
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 19. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling.
    Dahl CP, Husberg C, Gullestad L, Waehre A, Damås JK, Vinge LE, Finsen AV, Ueland T, Florholmen G, Aakhus S, Halvorsen B, Aukrust P, Oie E, Yndestad A, Christensen G.
    Circ Heart Fail; 2009 Nov 02; 2(6):624-32. PubMed ID: 19919988
    [Abstract] [Full Text] [Related]

  • 20. Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.
    Ruetten H, Gehring D, Hiss K, Schindler U, Gerl M, Busch AE, Schaefer S.
    Br J Pharmacol; 2005 Nov 02; 146(5):723-31. PubMed ID: 16151439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.